{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:40:18Z","timestamp":1781498418921,"version":"3.54.1"},"reference-count":121,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.00343","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T05:06:11Z","timestamp":1583989571000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":54,"title":["Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?"],"prefix":"10.3389","volume":"10","author":[{"given":"Luca","family":"Cantini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffit","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Sterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G. J. V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/sj.bjc.6690105","article-title":"The European mesothelioma epidemic","volume":"79","author":"Peto","year":"1999","journal-title":"Br J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"790","DOI":"10.2471\/blt.13.132118","article-title":"Asbestos: use, bans and disease burden in Europe","volume":"92","author":"Kameda","year":"2014","journal-title":"Bull World Health Organ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1136\/oem.17.4.260","article-title":"Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province","volume":"17","author":"Wagner","year":"1960","journal-title":"Br J Ind Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1517\/13543784.2013.816281","article-title":"Therapies currently in Phase II trials for malignant pleural mesothelioma","author":"Pinton","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/ng.3520","article-title":"Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations","volume":"48","author":"Bueno","year":"2016","journal-title":"Nat Genet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/0008-5472.CAN-14-1008","article-title":"Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma","volume":"75","author":"Guo","year":"2015","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1097\/JTO.0000000000000436","article-title":"Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study","volume":"10","author":"Lo Iacono","year":"2015","journal-title":"J Thorac Oncol"},{"key":"B9","first-page":"2331","article-title":"Genome-based mutational analysis by next generation sequencing in patients with malignant pleural and peritoneal mesothelioma","volume":"36","author":"Ugurluer","year":"2016","journal-title":"Anticancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e106742","DOI":"10.1371\/journal.pone.0106742","article-title":"Ratio of intratumoral macrophage phenotypes is a prognostic factor in epithelioid malignant pleural mesothelioma","volume":"9","author":"Cornelissen","year":"2014","journal-title":"PLoS ONE"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e1009285","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00262-010-0881-6","article-title":"CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection","volume":"59","author":"Yamada","year":"2010","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","article-title":"Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute","volume":"23","author":"Van Meerbeeck","year":"2005","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lungcan.2010.12.004","article-title":"Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma","volume":"72","author":"Ceresoli","year":"2011","journal-title":"Lung Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3978\/j.issn.2225-319X.2012.11.05","article-title":"Standardizing surgical treatment in malignant pleural mesothelioma","volume":"1","author":"Rice","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"B17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","article-title":"Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: Results in 663 patients","volume":"135","author":"Flores","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/JTO.0b013e31824ab6c5","article-title":"Pleurectomy\/decortication is superior to extrapleural pneumonectomy in the multimodality management of patients with malignant pleural mesothelioma","volume":"7","author":"Lang-Lazdunski","year":"2012","journal-title":"J Thorac Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1200\/JCO.2016.67.2675","article-title":"Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma","volume":"34","author":"Rimner","year":"2016","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.21037\/jtd.2017.10.165","article-title":"The role of intracavitary therapies in the treatment of malignant pleural mesothelioma","volume":"10","author":"Bertoglio","year":"2018","journal-title":"J Thorac Dis"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1016\/j.jtho.2018.06.011","article-title":"Scientific advances and new frontiers in mesothelioma therapeutics","volume":"13","author":"Mutti","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"8555","DOI":"10.1200\/jco.2017.35.15_suppl.8555","article-title":"Effect of FAK inhibitor defactinib on tumor immune changes and tumor reductions in a phase II window of opportunity study in malignant pleural mesothelioma (MPM)","volume":"35","author":"Bueno","year":"2017","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.immuni.2016.07.011","article-title":"Tumor-specific T cell dysfunction is a dynamic antigen-driven differentiation program initiated early during tumorigenesis","volume":"45","author":"Schietinger","year":"2016","journal-title":"Immunity"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"7483","DOI":"10.1158\/1078-0432.CCR-17-2169","article-title":"A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma","volume":"23","author":"Zauderer","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e026779","DOI":"10.1136\/bmjopen-2018-026779","article-title":"Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: Rationale and design of the MESOPEC","volume":"9","author":"De Boer","year":"2019","journal-title":"BMJ Open"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1164\/rccm.200501-057OC","article-title":"Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells","volume":"171","author":"Hegmans","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1164\/rccm.200909-1465OC","article-title":"Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma","volume":"181","author":"Hegmans","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"v31","DOI":"10.1093\/annonc\/mdv199","article-title":"Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Baas","year":"2015","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"mdz394","DOI":"10.1093\/annonc\/mdz394.092","article-title":"LBA92Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19)","volume":"30","author":"Burgers","year":"2019","journal-title":"Ann Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"mdz266","DOI":"10.1093\/annonc\/mdz266.002","article-title":"1843OSAKK 17\/16 - Lurbinectedin as second or third line palliative chemotherapy in malignant pleural mesothelioma (MPM): A multi-center, single-arm phase II trial","volume":"30","author":"Metaxas","year":"2019","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/neuonc\/noy148.148","article-title":"CBMT-29. Induction of autophagy following TTFields application serves as a survival mechanism mediated by AMPK activation","volume":"78","author":"Shteingauz","year":"2018","journal-title":"Neuro Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1016\/s1470-2045(19)30532-7","article-title":"Tumour treating fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial","volume":"20","author":"Ceresoli","year":"2019","journal-title":"Lancet Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","article-title":"Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): A randomised, controlled, open-label, phase 3 trial","volume":"387","author":"Zalcman","year":"2016","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-2600(19)30139-0","article-title":"Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"7","author":"Scagliotti","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1002\/path.824","article-title":"Vascular endothelial growth factor is an autocrine growth factor in human malignant mesothelioma","volume":"193","author":"Strizzi","year":"2001","journal-title":"J Pathol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.jtho.2016.01.014","article-title":"A randomized phase II study adding axitinib to pemetrexed-cisplatin in patients with malignant pleural mesothelioma: A single-center trial combining clinical and translational outcomes","volume":"11","author":"Buikhuisen","year":"2016","journal-title":"J Thorac Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/JTO.0b013e31828c2b26","article-title":"Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy","volume":"8","author":"Papa","year":"2013","journal-title":"J Thorac Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1097\/JTO.0b013e3181ec18db","article-title":"A phase II study of sorafenib in malignant mesothelioma: results of cancer and leukemia group B 30307","volume":"5","author":"Dubey","year":"2010","journal-title":"J Thorac Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.cllc.2013.12.008","article-title":"Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma","volume":"15","author":"Tsao","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1200\/JCO.2017.72.9012","article-title":"Nintedanib plus pemetrexed\/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled lume-meso trial","volume":"35","author":"Grosso","year":"2017","journal-title":"J Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"8514","DOI":"10.1200\/jco.2018.36.15_suppl.8514","article-title":"SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma","volume":"36","author":"Tsao","year":"2018","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4340","DOI":"10.1158\/0008-5472.CAN-07-6705","article-title":"Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice","volume":"68","author":"Dineen","year":"2008","journal-title":"Cancer Res"},{"key":"B45","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","author":"Bott","year":"","journal-title":"Nature Genetics"},{"key":"B46","doi-asserted-by":"publisher","first-page":"10854","DOI":"10.1073\/pnas.92.24.10854","article-title":"High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas","volume":"92","author":"Bianchi","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"B47","first-page":"5547","article-title":"p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma","volume":"54","author":"Cheng","year":"1994","journal-title":"Cancer Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.celrep.2012.12.008","article-title":"Deciphering signatures of mutational processes operative in human cancer","volume":"3","author":"Alexandrov","year":"2013","journal-title":"Cell Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1158\/0008-5472.CAN-15-0295","article-title":"Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer","volume":"76","author":"Ohar","year":"2016","journal-title":"Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.canlet.2016.05.011","article-title":"CDKN2A and BAP1 germline mutations predispose to melanoma and mesothelioma","volume":"378","author":"Betti","year":"2016","journal-title":"Cancer Lett"},{"key":"B51","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/sj.onc.1201861","article-title":"BAP1: A novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression","volume":"16","author":"Jensen","year":"1998","journal-title":"Oncogene"},{"key":"B53","doi-asserted-by":"publisher","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"B54","doi-asserted-by":"publisher","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"key":"B56","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: A multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer","volume":"33","author":"Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1001\/jamaoncol.2015.5495","article-title":"Inherited mutations in women with ovarian carcinoma","volume":"2","author":"Norquist","year":"2016","journal-title":"JAMA Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/ijms20020429","article-title":"BAP1 status determines the sensitivity of malignant mesothelioma cells to gemcitabine treatment","volume":"20","author":"Guazzelli","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.it.2016.01.004","article-title":"The nature of myeloid-derived suppressor cells in the tumor microenvironment","volume":"37","author":"Kumar","year":"2016","journal-title":"Trends Immunol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis?","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"key":"B62","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/jcmm.12000","article-title":"PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT\/mTOR axis via SIRT1","volume":"17","author":"Pinton","year":"2013","journal-title":"J Cell Mol Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"Lafave","year":"2015","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"8515","DOI":"10.1200\/jco.2018.36.15_suppl.8515","article-title":"Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R\/R) malignant mesothelioma (MM) with BAP1 inactivation","volume":"36","author":"Zauderer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0092-8674(00)81079-X","article-title":"Role of the INK4a locus in tumor suppression and cell mortality","volume":"85","author":"Serrano","year":"1996","journal-title":"Cell"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1158\/1535-7163.MCT-14-0793","article-title":"CDKN2A\/p16 loss implicates CDK4 as a therapeutic target in imatinib-resistant dermatofibrosarcoma protuberans","volume":"14","author":"Eilers","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"B67","first-page":"11692","article-title":"CDK4\/6 inhibitor suppresses gastric cancer with CDKN2A mutation","volume":"8","author":"Huang","year":"2015","journal-title":"Int J Clin Exp Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","article-title":"Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer","volume":"17","author":"Konecny","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","first-page":"11501","DOI":"10.1073\/pnas.1001613107","article-title":"Pattern of retinoblastoma pathway inactivation dictates response to CDK4\/6 inhibition in GBM","volume":"107","author":"Wiedemeyer","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e24326","DOI":"10.1200\/jco.2018.36.15_suppl.e24326","article-title":"CDK4\/6 inhibitor and radiation therapy in malignant pleural mesothelioma","volume":"36","author":"Matsumoto","year":"2018","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1038\/bjc.2014.220","article-title":"Multipoint targeting of the PI3K\/mTOR pathway in mesothelioma","volume":"110","author":"Zhou","year":"2014","journal-title":"Br J Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-15-2225","article-title":"Phase I study of apitolisib (GDC-0980), dual phosphatidylinositol-3-kinase and mammalian target of rapamycin kinase inhibitor, in patients with advanced solid tumors","volume":"22","author":"Dolly","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2762","DOI":"10.1002\/ijc.25202","article-title":"Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer","volume":"126","author":"Delage","year":"2010","journal-title":"Int J cancer"},{"key":"B74","doi-asserted-by":"publisher","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1200\/JCO.2016.71.3230","article-title":"Phase 1 dose-escalation study of pegylated arginine deiminase, cisplatin, and pemetrexed in patients with argininosuccinate synthetase 1\u2013deficient thoracic cancers","volume":"35","author":"Beddowes","year":"2017","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pbio.1001906","article-title":"Tracking genomic cancer evolution for precision medicine: the lung TRACERx study","volume":"12","author":"Jamal-Hanjani","year":"2014","journal-title":"PLoS Biol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"TPS8576","DOI":"10.1200\/jco.2016.34.15_suppl.tps8576","article-title":"A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum\/pemetrexed-based chemotherapy (NCT02610140)","volume":"34","author":"Hassan","year":"2016","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"5787","DOI":"10.1158\/1078-0432.ccr-19-0070","article-title":"Clinical response of live-attenuated, listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2511","DOI":"10.1200\/jco.2019.37.15_suppl.2511","article-title":"Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent","volume":"37","author":"Adusumilli","year":"2019","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1159\/000339259","article-title":"Malignant pleural mesothelioma: from the bench to the bedside","volume":"83","author":"Astoul","year":"2012","journal-title":"Respiration"},{"key":"B81","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1097\/JTO.0000000000000177","article-title":"B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis","volume":"9","author":"Mansfield","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"e0121071","DOI":"10.1371\/journal.pone.0121071","article-title":"Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)","volume":"10","author":"Cedr\u00e9s","year":"2015","journal-title":"PLoS ONE"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1164\/rccm.201608-1755CI","article-title":"Checkpoint blockade in lung cancer and mesothelioma","volume":"196","author":"Lievense","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"mdz394","DOI":"10.1093\/annonc\/mdz394.091","article-title":"LBA91_PRA multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso tri","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/1078-0432.ccr-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase 2 study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","article-title":"Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma","volume":"13","author":"Quispel-Janssen","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1016\/j.jtho.2018.08.007","article-title":"Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma","volume":"13","author":"Metaxas","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s40425-019-0608-y","article-title":"CD45RA+CCR7- CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab","volume":"7","author":"Kunert","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B93","doi-asserted-by":"publisher","first-page":"8503","DOI":"10.1200\/jco.2018.36.15_suppl.8503","article-title":"DREAM: A phase II study of durvalumab with first line chemotherapy in mesothelioma\u2014First results","volume":"36","author":"Nowak","year":"2018","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e705","DOI":"10.1016\/j.cllc.2018.05.001","article-title":"A phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma: a study protocol","volume":"19","author":"Fujimoto","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B95","doi-asserted-by":"publisher","first-page":"TPS8581","DOI":"10.1200\/jco.2017.35.15_suppl.tps8581","article-title":"Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma","volume":"35","author":"Zalcman","year":"2017","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ctrv.2015.09.006","article-title":"Targeting immune checkpoints: New opportunity for mesothelioma treatment?","volume":"41","author":"Marcq","year":"2015","journal-title":"Cancer Treat Rev"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s00262-018-2191-3","article-title":"Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge","volume":"67","author":"Calabr\u00f2","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B98","doi-asserted-by":"publisher","first-page":"CT039","DOI":"10.1158\/1538-7445.AM2017-CT039","article-title":"Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors","volume":"77","author":"Angevin","year":"2017","journal-title":"Clin Trials"},{"key":"B99","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.09.001","article-title":"Nuclear FAK controls chemokine transcription, tregs, and evasion of anti-tumor immunity","volume":"163","author":"Serrels","year":"2015","journal-title":"Cell"},{"key":"B100","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1158\/1538-7445.am2017-5569","article-title":"Abstract 5569: The impact of ADI-PEG20 on PDL1 expression in ASS1 deficient uveal melanoma","volume":"77","author":"Khadeir","year":"2017","journal-title":"Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1200\/jco.2018.36.15_suppl.2556","article-title":"A phase Ib study of ADI-PEG 20 plus pembrolizumab in advanced solid cancers","volume":"36","author":"Chang","year":"2018","journal-title":"J Clin Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1200\/jco.2019.37.8_suppl.29","article-title":"A phase II single-arm study of CRS-207 with pembrolizumab (pembro) in previously treated malignant pleural mesothelioma (MPM)","volume":"37","author":"Alley","year":"2019","journal-title":"J Clin Oncol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jtho.2016.10.003","article-title":"The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC","volume":"12","author":"Manegold","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.2217\/imt.12.108","article-title":"Dendritic cell-based immunotherapy in mesothelioma","volume":"4","author":"Cornelissen","year":"2012","journal-title":"Immunotherapy"},{"key":"B105","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/(SICI)1097-0215(19971104)73:3<309::AID-IJC1>3.0.CO;2-3","article-title":"Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma","volume":"73","author":"Enk","year":"1997","journal-title":"Int J Cancer"},{"key":"B106","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1006\/cimm.1996.0139","article-title":"Dendritic cells in antitumor immune responses. I. Defective antigen presentation in tumor-bearing hosts","volume":"170","author":"Gabrilovich","year":"1996","journal-title":"Cell Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.3389\/fimmu.2018.02804","article-title":"Current state of dendritic cell-based immunotherapy: opportunities for in vitro antigen loading of different DC subsets?","volume":"9","author":"Huber","year":"2018","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.3389\/fimmu.2018.02759","article-title":"Combination strategies to optimize efficacy of dendritic cell-based immunotherapy","volume":"9","author":"van Gulijk","year":"2018","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.omto.2019.03.007","article-title":"Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment","volume":"13","author":"Belderbos","year":"2019","journal-title":"Mol Ther Oncolytics"},{"key":"B110","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1158\/1078-0432.CCR-17-2522","article-title":"Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: From mouse to human","volume":"24","author":"Aerts","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B111","doi-asserted-by":"publisher","first-page":"280","DOI":"10.21037\/tlcr.2019.05.05","article-title":"A multicenter, randomized, phase II\/III study of dendritic cells loaded with allogeneic tumor cell lysate (MesoPher) in subjects with mesothelioma as maintenance therapy after chemotherapy: DENdritic cell Immunotherapy for Mesothelioma (DENIM) trial","volume":"8","author":"Belderbos","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"261ra151","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"B113","doi-asserted-by":"publisher","first-page":"4198","DOI":"10.1182\/blood-2018-99-119502","article-title":"Sequential anti-CD19 directed chimeric antigen receptor modified T-cell therapy (CART19) and PD-1 blockade with pembrolizumab in patients with relapsed or refractory B-Cell non-hodgkin lymphomas","volume":"132","author":"Chong","year":"2018","journal-title":"Blood"},{"key":"B114","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1038\/bjc.2015.481","article-title":"Oncolytic viruses: finally delivering","volume":"114","author":"Seymour","year":"2016","journal-title":"Br J Cancer"},{"key":"B115","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1165\/rcmb.2010-0026RT","article-title":"Gene therapy for mesothelioma and lung cancer","volume":"42","author":"Vachani","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3389\/fonc.2017.00179","article-title":"Oncolytic viral therapy for mesothelioma","volume":"7","author":"Pease","year":"2017","journal-title":"Front Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1164\/rccm.201103-0554CR","article-title":"A trial of intrapleural adenoviral-mediated interferon-\u03b12b gene transfer for malignant pleural mesothelioma","volume":"184","author":"Sterman","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"3791","DOI":"10.1158\/1078-0432.CCR-15-2133","article-title":"Pilot and feasibility trial evaluating immuno-gene therapy of malignant mesothelioma using intrapleural delivery of adenovirus-IFN\u03b1 combined with chemotherapy","volume":"22","author":"Sterman","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B119","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1245\/s10434-006-9127-4","article-title":"Radiation-induced cellular DNA damage repair response enhances viral gene therapy efficacy in the treatment of malignant pleural mesothelioma","volume":"14","author":"Adusumilli","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"B121","volume-title":"22 Case Studies Where Phase 2 and Phase 3 Trials had Divergent Results","year":"2017"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00343\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T05:06:16Z","timestamp":1583989576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.00343\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":121,"alternative-id":["10.3389\/fonc.2020.00343"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.00343","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"article-number":"343"}}